Biogen’s Alzheimer’s drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings. Source

JOIN NCOV.LINK NEWSLETTER

And get notified everytime we publish a new Important announcements. We will not email you often, unless there are important things that need to get in touch with you, such as added new tools or new domain names.